View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Simen Mortensen
  • Simen Mortensen

More Q1 results and a proposed delisting

The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

Jørgen Lian
  • Jørgen Lian

Avance Gas (No_rec, TP: NOK) - Discontinuing coverage

We have discontinued coverage of Avance Gas, as it no longer has any assets, and does not plan to make any new investments. According to the company, remaining funds after its final USD0.74 DPS, to be paid on 7 May (ex-date 24 April), are expected to be used to settle any outstanding obligations to creditors, including liquidation fees, and the stock is expected to be delisted in June/July 2025. Our last published recommendation, target price and estimates should no longer be relied upon.

Simen Mortensen
  • Simen Mortensen

Signs of sector recovery, and more Q1 results

The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...

 PRESS RELEASE

Avance Gas Holding Ltd: First Quarter 2025 Earnings Release

Avance Gas Holding Ltd: First Quarter 2025 Earnings Release HIGHLIGHTS Net profit of $42.6 million and earnings per share of $0.56 for the first quarter 2025, compared to net income of $210.2 million and earnings per share of $2.74 for the fourth quarter 2024. On February 28, 2025, the sale of the four Mid-Sized Gas Carriers (“MGCs”) newbuilding contracts to subsidiaries of Exmar LPG B.V. (“Exmar”) was successfully completed. Avance Gas received reimbursement of $62.1 million of yard instalments paid by Avance Gas to the yard. The Company recorded a gain on sale of $34.2 million in relatio...

 PRESS RELEASE

Avance Gas Holding Ltd (OSE: AGAS) (“AGAS” or the “Company”) – Notice ...

Avance Gas Holding Ltd (OSE: AGAS) (“AGAS” or the “Company”) – Notice of Special General Meeting Reference is made to the press releases issued by the Company on 27 November 2024, in connection with Third Quarter 2024 Earnings, and on 6 December 2024, which stated the intention to wind-up AGAS. In preparation for this, the Company advises that a special general meeting of the Company will be held on 16 May 2025 (the “SGM”) for its shareholders to consider and approve the liquidation of the Company and the delisting of the Company’s common shares from the Oslo Stock Exchange.  A copy of the...

 PRESS RELEASE

Avance Gas Holding Ltd: Ex Dividend USD 0.74 today - final distributio...

Avance Gas Holding Ltd: Ex Dividend USD 0.74 today - final distribution Hamilton, Bermuda, April 24, 2025 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.74 per share as of today relating to the final extraordinary distribution announced on April 16, 2025. The dividend will be paid on May 7, 2025. For further information, please contact: Randi Navdal Bekkelund, CFO Email: Tel: This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Jørgen Lian
  • Jørgen Lian

Another abrupt change

The US Trade Representative on 17 April published revised US port fees with significant changes to the initial proposal based on industry feedback. In its current form, the fees will primarily discourage use of Chinese-controlled maritime trade services to the US, and directly affect the use of Chinese-built vessels in US ports (with several considerable exemptions to avoid harm to US trade). The previous broader fees based on fleet composition and share of Chinese-built vessels has been scrappe...

 PRESS RELEASE

Avance Gas Holding Ltd: Key information relating to the final extraord...

Avance Gas Holding Ltd: Key information relating to the final extraordinary distribution of USD 0.74 per share Hamilton, Bermuda, April 16, 2025 Reference is made to the announcement on April 16, 2025, of final extraordinary distribution of $0.74 per share:Return of capital: $0.16 Dividend: $0.58Declared currency: USDLast day including right: April 23, 2025Ex-date: April 24, 2025Record date: April 25, 2025Payment date: May 7, 2025Date of Approval: April 15, 2025 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

 PRESS RELEASE

Avance Gas Holding Ltd: Final extraordinary distribution of USD 0.74 p...

Avance Gas Holding Ltd: Final extraordinary distribution of USD 0.74 per share Hamilton, Bermuda. April 16, 2025 This refers to the Fourth Quarter 2024 Earnings Release announced on February 12, 2025. In that release, the Company stated that it would distribute a final dividend of approximately $0.70 per share upon receiving the remaining $34.2 million from Exmar in connection with the sale of the four Mid-Sized Gas Carriers (MGCs). We are pleased to announce that the final settlement with Exmar has been received. As a result, the Company will proceed with a final extraordinary distributio...

Niklas Wetterling
  • Niklas Wetterling

Fabege (Hold, TP: SEK85.00) - Soft start to 2025

The Q1 results were soft: 1) Profit from property management was 16% below consensus; 2) the EPRA vacancy rate rose to 13.8% (12.4% last quarter); and 3) market rents appeared to decline in some submarkets as renegotiations in Q1 dropped by 4.8% and Fabege wrote down asset values by 0.7% mainly on lowered market rent expectations. The equity story remains weak, with no turning point in sight and a soft FFOPS growth outlook, in our view. We reiterate our HOLD but have cut our target price to SEK8...

ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Markus Henriksson
  • Oscar Lindquist
ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Markus Henriksson
  • Oscar Lindquist
Simen Mortensen
  • Simen Mortensen

Q1 reporting begins, volatility persists, CEO to leave and ‘special ex...

The ‘tariff volatility’ in credit and equity markets persisted this week, reversing many of the gains from previous weeks. Atrium Ljungberg kicked off Q1 reporting season. Öresund’s representative left the board of Stenhus and appointed a special examiner to review the company’s management. Castellum’s CEO Joacim Sjöberg stated he plans to leave by Q4 2026. The weighted-average implied EBITDA yields on the stocks we cover are 5.33% for 2025e and 5.66% for 2026e.

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Subdued prescription growth in Q1

We have updated our model with the latest IQVIA data, and see downside risk to Visible Alpha consensus. We see Q1e global sales for Wegovy of DKK17,898m (c2.2% below consensus) and Ozempic of DKK31,642m (c1.5% below consensus). While a reaffirmation of guidance could offer relief, we have lowered our target price, primarily on lower-than-expected GLP-1 sales. We reiterate our BUY but have cut our target price to DKK900 (1,040).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch